Indoco Remedies Ltd (INDOCO) is currently trading at 248.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Indoco Remedies Limited is a Mumbai-based pharmaceutical company engaged in manufacturing and marketing pharmaceutical formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The company has showcased strong performance in its exports division, especially in emerging markets and its subsidiaries like FPP in the U.S. and Warren Remedies, with a notable increase in OTC business. Indoco has launched product extensions in India’s OTC market, including products like Sensodent DSP and Sensodent DPC, enhancing its presence in sensitivity protection and clean toothpaste segments. Indoco's API segment has seen growth, with significant developments like receiving the EIR for its Patalganga site from the USFDA, indicating strong regulatory compliance and operational standards. Despite challenges in its acute therapies segment impacting domestic sales, Indoco has achieved rank 21st in India's prescription audit, moving past major players like Pfizer.

Over the past 52 weeks, Indoco Remedies Ltd has traded between a low of ₹163.70 and a high of ₹317.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Indoco Remedies Ltd has a market capitalization of approximately 2,301.59. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Indoco Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 742.45 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,301.59 Cr, Indoco Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Indoco Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Indoco Remedies Ltd is 742.45. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Indoco said the USFDA completed a routine inspection of its Patalganga, Navi Mumbai API facility in September 2025 with zero Form 483 observations.

Consolidated profit attributable to equity shareholders was reported at ₹64.99 crore in Q1 FY27, compared with a loss of ₹35.79 crore in Q1 FY26.

Indoco Remedies reported a standalone net profit of ₹8.23 crore for Q1FY27, compared with a net loss of ₹2.81 crore in Q1FY26.

Standalone revenue from operations was ₹40.81 crore and standalone net profit was ₹8.23 crore for the quarter ended June 30, 2026.